April 2026 update

In short

More than 250 people with Parkinson's had been dosed. The update described revised dosing protocols and manufacturing changes, and said research interest was widening to other conditions linked to blood vessel health.

April's update said the March issue had drawn a strong response from readers, with many questions about FGF-1. It repeated the team's description of FGF-1 as a protein found in all animals and present in the human body from before birth, which the team believes plays a part in repairing cells.

A new dosing protocol

Parkinson's remained one of Zhittya's two main research efforts. The update said a new protocol, the written plan a study follows, had raised the FGF-1 dose. It also said a new manufacturing facility was producing a more potent form of the protein.

The team said it was very pleased with what it saw in participants after these changes.

First participants in other brain conditions

The update said that in April the team would begin dosing the first participants in five new research areas. Four involve the brain and nervous system: recovery after a stroke that happened years earlier, cerebral palsy, aphasia (a loss of the ability to use or understand language) and multiple sclerosis. The fifth was in another research area.

Several of these were studies of a single person. The update was direct about what that means. If one participant with cerebral palsy improves over the next two years, it said, that will not show that FGF-1 helps in cerebral palsy, because one person is too small a number.

The chief executive wrote that research has to start with a first participant, then a second, before larger studies are possible. He thanked the volunteers who had stepped forward to go first.

For multiple sclerosis, the update said the team and a number of neurologists believe the disease involves the endothelial cells, the cells that line blood vessels. Zhittya also shared a white paper, a background document, on that topic.

Blood vessels and the published research

The update repeated a point from March. According to the team's AI-assisted search, the first paper on FGF-1 and the repair of blood vessel cells appeared in October 1991 in the Proceedings of the National Academy of Sciences. The search counted more than 630 papers on that topic since, and more than 4,000 on FGF-1 and blood vessel repair and growth.

The chief executive wrote that he believes worn-out blood vessel cells are a root cause of many illnesses of aging, including brain disorders. He presented this as his own strong belief.

Four years of Parkinson's research

The update noted that May 2026 would mark four years since the first two participants with Parkinson's received FGF-1. It said the first results were encouraging and that more than 250 people with Parkinson's had been dosed since.

The update shared four messages from participants. Topics included tremor, stiffness, smoother movement, facial expression, the sense of smell, sweating and night vision.

One participant described the new nebulizer routine: about 15 seconds of dosing, then a minute of rest, repeated until the small vial is empty. A nebulizer turns liquid into a fine mist.

The chief executive noted that the nebulizer is the fifth device the team has used in three and a half years, and that the search for a better one continues. The brain imaging study at Washington University in St. Louis was also continuing.

This summary covers the Parkinson's research in the April 2026 update. The complete update, including the other topics it covered, is below.

Read the complete April 2026 update as published

The text of the update Zhittya sent, word for word. Pictures, charts and layout are in the PDF. Open the PDF.

April 17, 2026 Monthly Update

The last 30 days - Wow!

The March 17th Update has been very well received by our over 120,000 Update subscribers. We have had outstanding inquiries and discussions from many people about our FGF-1 medicine. It seems we have opened some people’s minds by explaining in the March Update that this molecule has been around for over 600 million years, that it is found in all animals, and that FGF-1 “rejuvenates” the human body at the cellular level. A lot of people have come to the realization that this medicine is real medical science, and also to the realization that FGF-1 has already been repairing our bodies every day since before we were born. The realization that people can now utilize FGF-1 in a medical therapeutic way to recover their health is dawning on many people who have serious health issues.

Zhittya’s two main medical research efforts include treating (1) Parkinson’s disease and (2) reversing type-2 diabetes, and there have been some very exciting developments over the last 30 days. Vika’s new Protocol has increased the FGF-1 dosage, and our new FGF-1 manufacturing facility is delivering a more potent FGF- 1 dose. We are very pleased with what we see as enhanced outcomes in patients. The type 2 diabetes data is now flowing to us, and we are learning more about the treatment for type 2 diabetes and many collateral issues that provide hints of very encouraging things to come to us in the future. It is too early, and we have too small a sample size of patients to go public with this; however, I pray this data holds up, as it could be a very big deal.

Given the surge of interest in Zhittya’s Freedom to Try policy, we will be starting to dose patients in five new medical indications beginning in April. These indications include:

1) Enhanced Stroke Recovery. This is a person who has had a stroke and has had some recovery over the years, but, after several years, the person still has unresolved issues and wants to try to enhance his recovery with FGF-1 usage. Millions of people are suffering from ongoing stroke disabilities. We believe FGF-1 can continue their recovery to a better state of function. Our first patient was dosed in April.

2) Cerebral Palsy. This disorder is reported to affect around 800,000 Americans. It is recognized as a vascular dysfunctional issue. A sufferer of cerebral palsy wanted to be in Zhittya’s type 2 diabetes Medical Research Study; however, his cerebral palsy was an exclusion criterion for that study's protocol. So, we asked him if he would consider being the first person in a Medical Research Study to potentially enhance his cerebral palsy. He liked the idea and is scheduled to be dosed later this month. Please note: I hope, like our Parkinson’s disease patients who have had their blood flow in their brains scanned and shown increased blood flow after dosing with FGF-1, that our patient with cerebral palsy will experience the same enhanced blood flow in his brain, resulting in an improvement in his neurons and an improvement in his functionality. If, over the next two years, we see him improve, it will not prove that we have a treatment for cerebral palsy, since the number of people in the study (one) is too small. What it will mean to me is that we might have a treatment to enhance the lives of 800,000 people in the United States and the estimated 18 million sufferers worldwide.

3) Aphasia. This disorder is reported to affect over 2 million Americans. The father of one of our collaborating neuroscientists (who believes in our medicine) has aphasia. The neuroscientist believes FGF-1 is safe in the brain, since he has taken it himself. He asked me if we would try it on his father. We are not aware of any treatment to reverse Aphasia, but we believe FGF-1 might be able to reverse it. This person will be dosed with FGF-1 in April.

4) Multiple Sclerosis: This disorder is reported to affect around one million people in the United States. We, and a good number of other neurologists, believe multiple sclerosis (MS) is a disease of the vascular system (endothelial dysfunction). It is known in the medical literature that FGF-1 can repair endothelial dysfunction. Now with the new dosing protocol, we believe we might be able to heal those leaking vessels and resolve multiple sclerosis. The first person with MS will be dosed in April. 5) Prophylactic Use for Vascular Dysfunction. We have written (and I strongly believe) that endothelial dysfunction is the root cause of death and aging in the world. As the blood vessels (endothelial cells) age and wear out, they start to leak and become dysfunctional. This results in the blood to your heart, brain, lungs, kidneys, liver, legs, skin and other organs suffering from a lack of nourishment. I believe the root cause of heart disease, brain disorders and more is the disruption of blood circulation, due to endothelial cell dysfunction. In our March 17 Update, we showed that based on AI research over the last 30 years, FGF-1 can repair and rejuvenate endothelial cells. The reason your doctor or other medical experts do not talk about treating the root cause of many illnesses and your aging is that they do not know about the medical research which demonstrates that FGF-1 can heal this condition. One gentleman asked to be the test subject in a one-person Medical Research Study for prophylactic treatment of his endothelial cells. We have cleared it, and he will be dosed in April. He is in his mid-60’s and in apparent good health and wants to rejuvenate his endothelial cells before they become dysfunctional (just like I have been doing over the last three years!).

To remind you of what was written in the March 17 Update on endothelial dysfunction:

Question #5: Can FGF-1 repair blood vessels at a cellular level?

Answer: The first paper on this topic was published in October 1991 in The Proceedings of the National Academy of Sciences. Over 630 papers have been published on endothelial regeneration by FGF-1 and over 4,000 papers published in the last 30 years on FGF-1 and blood vessel repair and growth.

Dan Montano’s Comment: Why is this important? It is important because endothelial cell dysfunction leads to aging and death. When your endothelial cells that make up your blood vessels cannot repair themselves, your time on this earth is ending!

Concierge Single Patent Medical Research Studies

The March 17 Update and its lengthy list of 30 to 40 years of medical research on what FGF-1 has done or should be able to do, has stimulated some of our readers to explore the idea of them doing a private Medical Research Study for their specific medical need. May 2026 will be the 4-year anniversary since we first dosed two Parkinson’s disease patients in the British Virgin Islands to see if FGF-1 could reverse their neurodegenerative disease. The first results were encouraging. From that first glimpse of success, Zhittya has now treated over 250 Parkinson’s disease sufferers. Read the patient comments in Vika’s section of this Update, those Parkinson’s disease patients are improving, and they are happy to be healing instead of degenerating like other Parkinson’s disease patients who have not received FGF-1. I recently attended a Financial Investors Conference where I presented on our success (total of 85 people, 25 patients from the BVI and 60 from Las Vegas) on reversing their type 2 diabetes. At this conference, one financial expert in biotech told me our data was worthless. He stated, “Until you have clinical evidence from over 1,000 people and FDA clearance, your data is not real.” Read the type 2 diabetes test subjects’ comments on how their lives are better already from being in this study. More importantly, how does this critic think you get data from 1,000 people? I know the answer! You start with one, then you do another one, and then you have two, and then another, etc., etc.

We believe FGF-1 can enhance the lives of people suffering with long term stroke disabilities, cerebral palsy, aphasia, multiple sclerosis, and much more. I respect the man who has lived with cerebral palsy his entire life. He has succeeded and made the world a better place by his life’s actions. He has volunteered to be the first to explore if FGF-1 can stimulate new vascular perfusion, which would cause his own neural stem cells to divide, migrate, differentiate, and then integrate into his brain to enhance his mental functions. I love this man for stepping forward, not just for himself, but maybe showing the path forward to help millions of others facing cerebral palsy and have no hope of improvement. Yes, a thousand- patient study and FDA approval would be great; however, you have to start with the #1 patient and see if it works first.

Zhittya is advancing, and I thank all the people who are coming forward to help show us the way. Discovery starts with one person doing something no one has ever done before. If the FDA eventually approves FGF-1 to treat cerebral palsy after a 10,000-person study and the study is completed in 2033, I will always know that it all started with Artur, one man with faith!

Zhittya’s White Paper on Multiple Sclerosis

Here is a link to Zhittya’s White paper (on FGF-1 treating Multiple Sclerosis for your information: Link: zgm.care/multiple-sclerosis Status of Funding for Zhittya’s Medical Research Studies

Type-2 Diabetes:

Zhittya has effectively completed the funding of the Medical Research Study to treat 100 type-2 diabetic patients in Las Vegas. We are happy with the medical results so far. We are also pleased that with a very small marketing budget; we are obtaining about 200 new sign-ups per day for our type 2 diabetes study. It seems people who have diabetes do not want to keep it! I believe we should be completed with dosing by the end of May and have preliminary data to report by this May/June. I have been very pleased so far.

No Option Heart Disease: Note: Heart disease is the leading cause of death in the world.

Zhittya and The Bahamas Heart Centre are conducting a 100-person Medical Research Study to treat no-option heart disease patients with FGF-1, as we have done in three other successful heart studies. Zhittya is raising $10 million USD to fund this Medical Research Study for no-option heart patients. We have seen 100% success with zero adverse events in the last 30 years and believe that the millions of people confronted with certain death would travel to The Bahamas to save and extend their lives.

If you are interested in learning more about the investment opportunity for the Medical Research Study to treat “Small Vessel Heart Disease” (minimum investment of $25,000), please email me at Dan333@aol.com or call me at 702- 802-8373. The investment has the following benefits:

50% royalty on Zhittya’s revenue for the treatment of small vessel heart disease (up to 10x the original investment)
A put option where investors can receive 2x their original investment after 48 months if they are not happy!

I believe the demand among these rich people to save their lives and live longer will be strong.

If heart disease runs in your family, you might be able to invest, make money, and benefit your health and life. Besides making money, you can advance medical innovation to benefit millions of people.

I believe Zhittya’s business model for treating the #1 cause of death in the world (small vessel heart disease) is a good deal for everyone.

Chronic Wounds: Diabetic Foot Ulcers (DFUs)

In October 2025, Zhittya raised one million dollars in a few weeks (out of the $5 million we sought) to carry out the Medical Research Study to treat chronic wounds. We raised one million dollars very quickly and were pleased with the interest of the investors. We were more pleased that, as word got out about what we were doing, companies that conduct animal studies and Phase I and II clinical studies in this area came knocking at our door, asking for work. It seems the billions of dollars that went into biotech during the Pandemic boom era have now disappeared. In 2025, the new FDA management is saying that less animal testing should be done. That resulted from 600 biotech companies failing every year in 2022, 2023, 2024, and 2025 because no venture capitalist was willing to invest, as they are no longer hot for COVID-19 biotech anymore. We received quotes for tasks that were amazingly low. Besides the price being low, they could all start now and be done soon. We would have no years of waiting behind a thousand biotech companies that no longer exist. We have decided to take advantage of the cost savings opportunity to get IND applications submitted for the Phase I study as fast as possible. For those of you that are worried: I do not have survivor’s guilt that Zhittya survived when thousands of biotech companies have failed. We fought and sacrificed to get Zhittya through the storm, and some smooth sailing has been earned by the team!

If you want more information on Zhittya’s diabetic foot ulcer program, go to: cure-wounds.com

If you are interested in learning more about the investment opportunity for the Medical Research Study to treat “Chronic Wounds- Diabetic Foot Ulcers” (minimum investment of $25,000), please email me at Dan333@aol.com or call me at 702-802-8373. The investment has the following benefits:

50% royalty on Zhittya’s revenue for the treatment of wounds (up to 10x the original investment)
A put option where investors can receive 2x their original investment after 48 months if they are not happy! Medical Research Studies info Zhittya will be utilizing Medical Research Studies to advance the development of our medicines. We believe it is better to partner with investors who have a passion for what we are doing, rather than a heartless venture capitalist who would sell us to the devil for a quick profit.

To learn more, here is an article from Nature magazine that explains how these Medical Research Studies funded in the 1980s led to the biotech giants that exist today: zgm.care/invest Vika’s Section: Patient Messages:

#1) Dear Vika, Yesterday was World Parkinson's Day. I helped by volunteering to sit at an information table for our local Parkinson's group. My husband and I go to a Parkinson’s ballet exercise class but don't go to any group meetings/support groups. The reason we don't is because it is depressing to see people further along than I am and we try to stay positive and hopeful. (Not trying to make anyone feel bad about where they are in their disease progression). With all that said, I met many people with Parkinsons and 2 of them I had conversations with about their illness and medications. One lady takes 6 pills a day and struggles with remembering to take them. She had a slight right-hand tremor that I noticed as well as other issues she verbalized to me. The other lady has a pump from Abbvie that releases the drug VYALEV. This lady also had a slight hand tremor that was noticeable. She too voiced other symptoms to me. (Brain fog, gut issues, fatigue, etc )

The next morning, I was talking to my husband about these ladies, and he reminded me that I still don't take any medication for Parkinsons since the end of 2023! He also reminded me that I still don't have an increase in symptoms. I have a slight tremor in my right hand that is much better since starting fgf1. I have some rigidity and gut issues but nothing that slows me down. I have also received the good results from my mri's (14% improvement!) I say all of this because I am thankful, I found Zhittya and that the fgf1 has helped me and held off other symptoms of this disease. Thank you for all of your help and for all of your efforts to help find a cure for PD! I pray that God will cure me and others!

Melissa

#2 Hi Vika,

Tomorrow will be my 2nd day of dosing using the new protocol of 15 seconds of dosing followed by 1 minute resting between dosing until the small vile of FGF-1 is completely gone. Using the nebulizer is an ideal method of dosing compared with the older less than ideal spray! Especially with my number of years. Thank you for coming up with this better alternative.

Hope all is well with the Montano's! Kind regards,

Roy

#3 Dear Vika:

The very next day after our first day of treatment, my husband and I noticed along with several others in the group had faces that had softened. We refer to ourselves as The Faces of Hope.

My family have noticed that my movements are smoother than before. Several months after treatment I walked through the kitchen while my son was making eggs and I asked, “what is that smell?” I didn’t even know my smell was not working.

Cindy

#4) Dear Vika, Also, unexpected bonus after 2nd dose - all my life I’ve had the problem of sweating excessively. Since dose 2, I’m like a “normal” person who only sweats with cause like exercise or heat. Night sweats are reduced by about 80-90%!!

I can’t wait for dose 3 :-)

My night vision has improved!

I’ve started a spreadsheet with my pd motor symptoms, non-motor symptoms and non-pd symptoms that are improving with FGF-1 treatment. Still a work in progress, but once I get it worked out, I’ll share. Beth

Cross Border Medical Tourism

Cross Border Medical Tourism services are for those people who want to be considered for Zhittya’s future clinical trials or its current Medical Research Studies. Cross Border is now arranging Medical Tourism to treat Parkinson’s disease in Las Vegas, which started in January 2026.

Cross Border is working on filling the Las Vegas Medical Research Studies (intranasal FGF-1 for Parkinson’s disease, Type-2 diabetes and more) on the following dates:

Cohort #46 April 27 – 30, 2026

Cohort #47 May 25 – 28, 2026

Cohort #48 June 23 – 25, 2026

Please contact Sam Cross at Cross Border Medical if you wish to be considered for one of these cohorts. Sam’s email address is: Sam.crossbordermedical@gmail.com

His phone number is: 714-393-8605

In addition, if you are interested in participating in a functional MRI brain scan study at Washington University in St. Louis, please let Sam know. There is a finite number of slots for the imaging studies. These studies will look at brain blood flow before and after treatment with FGF-1.

Events: May 14 – 16: Money Show in Dallas, Texas

Hilton DFW Lakes Executive Conference Center, Grapevine, Texas

Topic: Breakthrough Biotech Medicine for treating the cause of death for 65% of all adults ___________________________________________________________________ July 9 – 11: Freedom Fest in Las Vegas, Nevada Caesars Palace, Paradise, Nevada Zhittya will be making a Main Stage presentation on Zhittya’s medicines at the Freedom Fest.

In addition, on July 10, 2026, Zhittya is sponsoring a dinner on: “Freedom to Try Medical Innovations”. I hope we will have several hundred people attend this event, and I will be presenting. I also hope we will have a noted VIP guest speaker to address this important topic.

July 20 – 22: Money Show in Las Vegas, Nevada

Caesar’s Palace, Paradise, Nevada Breakthrough Biotech Medicine for treating the cause of death for 65% of all adults

July 22 – 25: Caribbean Cardiac Society 39th Annual Cardiology Conference

Atlantis Paradise Island-Bahamas

Zhittya will be presenting on its heart medicine to treat “Small Vessel Heart Disease”. Last year, this conference had around 350 attendees from all over the world. It is my hope that we can enlighten hundreds of cardiologists about a new treatment for their “No Option Heart Patients”.

August 26 – 28 Money Show San Francisco, California

Fairmont Hotel, San Francisco, California

Topic: Breakthrough Biotech Medicine for treating the cause of death for 65% of all adults ___________________________________________________________________ Conclusion by Dan Montano:

Every morning, I wake up, and I am excited about what new things I might learn and what new adventures await me. In the last 30 days, I have studied Cerebral

Palsy, Multiple Sclerosis, aphasia, and more, much, much more. Ideas on how we can utilize FGF-1 to treat more untreatable diseases race through my mind when I go to sleep, and now, I even dream about new applications for FGF-1 to treat sick people who have been told there is no hope for them. One of the greatest blessings of this adventure is the amazing people we have met and developed a long-term relationship with. Patients with Parkinson’s disease came to us with no hope, and now, after three years, they are good friends. As they improve, we find great happiness in seeing the fruit of our efforts. People who are dosed on Monday for their type 2 diabetes, call me, or Vika or others on our team, a few days later and claim, “I am no longer diabetic,” which is a gracious award to us.

I look into the future, and I see a thousand barriers and obstacles ahead of us to get our medical treatment to tens of millions of sick people. I think those obstacles should scare me, and yet I am so excited to contact them and find ways to resolve and overcome them. In 3 ½ years, Vika has been working on the best way to get FGF-1 up the nose. Now I believe we are on the fifth device, and it is working nicely, yet Vika keeps searching for a better one.

When a problem is presented to me, like this person who has cerebral palsy and is therefore excluded from the type 2 diabetes protocol, I see as clear as the morning sun rising over the Nevada desert, the path is to do a single trial for him. Was this a problem, an exclusion item, or a window of opportunity opening?

I believe by “Grace” we have opportunities every morning to serve others. I think of my beautiful aunt who died when her feet, and then her legs were amputated because of diabetic foot ulcers. I think of another aunt who had a stroke and became a vegetable for 15 years. I think of my best friend, the kindest and smartest person ever, Bob Levin, who could not remember me after being my “Soul” brother for 55 years. To my real brother, Ernest Montano, who passed away four months ago from a stroke. I owe many people for their gifts of love and friendship, which has blessed my life. This is what drives me: paying my debts to them and millions of others I have never met, nor will ever meet.

I believe we are very close to victory in our efforts to lessen pain and suffering and extend lives for millions of people.

God bless you and thank you all!

Dan Montano, CEO Zhittya Genesis Medicine

8683 W. Sahara Ave., Suite 280 Las Vegas, NV 89117 (USA) 702-802-8373 zgm.care

<https://www.zgm.care/multiplesclerosis>

[mailto:Dan333@aol.com](mailto:Dan333@aol.com)

<https://www.cure-wounds.com/>